Aldeyra Therapeutics Grants $88,000 Transition Bonus to Departing Chief Development Officer

Reuters01-01

Aldeyra <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Grants $88,000 Transition Bonus to Departing Chief Development Officer

Aldeyra Therapeutics Inc. has announced that Chief Development Officer Stephen G. Machatha, Ph.D., will resign from his position, effective on or before March 31, 2026. Under a new Transition Agreement, Dr. Machatha will continue to receive his current base salary and employee benefits until his departure. He will also be eligible for continued vesting of his outstanding stock options and restricted stock units during this transition period. In addition, Dr. Machatha will receive a lump sum payment of $88,000, representing 50% of his potential 2025 bonus based on 110% of his target bonus, in exchange for executing the Transition Agreement. If he executes an additional release of claims after his separation, he will be entitled to another lump sum payment of $88,000, representing the remaining 50% of his potential 2025 bonus.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-338394), on December 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2600584704?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-01 06:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600584704","market":"nz","top_or_hot":-1,"title":"Aldeyra Therapeutics Grants $88,000 Transition Bonus to Departing Chief Development Officer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aldeyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Grants $88,000 Transition Bonus to Departing Chief Development Officer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALDX\">Aldeyra Therapeutics Inc</a>. has announced that Chief Development Officer Stephen G. Machatha, Ph.D., will resign from his position, effective on or before March 31, 2026. Under a new Transition Agreement, Dr. Machatha will continue to receive his current base salary and employee benefits until his departure. He will also be eligible for continued vesting of his outstanding stock options and restricted stock units during this transition period. In addition, Dr. Machatha will receive a lump sum payment of $88,000, representing 50% of his potential 2025 bonus based on 110% of his target bonus, in exchange for executing the Transition Agreement. If he executes an additional release of claims after his separation, he will be entitled to another lump sum payment of $88,000, representing the remaining 50% of his potential 2025 bonus.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-338394), on December 31, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aldeyra Therapeutics Grants $88,000 Transition Bonus to Departing Chief Development Officer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAldeyra Therapeutics Grants $88,000 Transition Bonus to Departing Chief Development Officer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-01 06:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aldeyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Grants $88,000 Transition Bonus to Departing Chief Development Officer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALDX\">Aldeyra Therapeutics Inc</a>. has announced that Chief Development Officer Stephen G. Machatha, Ph.D., will resign from his position, effective on or before March 31, 2026. Under a new Transition Agreement, Dr. Machatha will continue to receive his current base salary and employee benefits until his departure. He will also be eligible for continued vesting of his outstanding stock options and restricted stock units during this transition period. In addition, Dr. Machatha will receive a lump sum payment of $88,000, representing 50% of his potential 2025 bonus based on 110% of his target bonus, in exchange for executing the Transition Agreement. If he executes an additional release of claims after his separation, he will be entitled to another lump sum payment of $88,000, representing the remaining 50% of his potential 2025 bonus.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-338394), on December 31, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALDX","symbol_name":"Aldeyra Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL1kgQgQ:1","article_id":"2600584704","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600584704","pubTimestamp":1767218868,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aldeyra Therapeutics Inc. has announced that Chief Development Officer Stephen G. Machatha, Ph.D., will resign from his position, effective on or before March 31, 2026. Under a new Transition Agreement, Dr. Machatha will continue to receive his current base salary and employee benefits until his departure. He will also be eligible for continued vesting of his outstanding stock options and restricted stock units during this transition period. In addition, Dr. Machatha will receive a lump sum payment of $88,000, representing 50% of his potential 2025 bonus based on 110% of his target bonus, in exchange for executing the Transition Agreement. If he executes an additional release of claims after his separation, he will be entitled to another lump sum payment of $88,000, representing the remaining 50% of his potential 2025 bonus.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Aldeyra Therapeutics向即将离任的首席开发官授予88,000美元过渡奖金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALDX":0.9},"content_text":"Aldeyra Therapeutics Grants $88,000 Transition Bonus to Departing Chief Development Officer\n    \n\nAldeyra Therapeutics Inc. has announced that Chief Development Officer Stephen G. Machatha, Ph.D., will resign from his position, effective on or before March 31, 2026. Under a new Transition Agreement, Dr. Machatha will continue to receive his current base salary and employee benefits until his departure. He will also be eligible for continued vesting of his outstanding stock options and restricted stock units during this transition period. In addition, Dr. Machatha will receive a lump sum payment of $88,000, representing 50% of his potential 2025 bonus based on 110% of his target bonus, in exchange for executing the Transition Agreement. If he executes an additional release of claims after his separation, he will be entitled to another lump sum payment of $88,000, representing the remaining 50% of his potential 2025 bonus.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-338394), on December 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600584704","isCrawlerRequest":true}